Last reviewed · How we verify

Arbidol (Umifenovir) — Competitive Intelligence Brief

Arbidol (Umifenovir) (Arbidol (Umifenovir)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Viral fusion inhibitor. Area: Infectious Disease / Virology.

marketed Viral fusion inhibitor Viral hemagglutinin (envelope protein) Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Arbidol (Umifenovir) (Arbidol (Umifenovir)) — Pharmstandard. Arbidol inhibits viral fusion by blocking the interaction between viral envelope proteins and host cell membranes, preventing viral entry into cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Arbidol (Umifenovir) TARGET Arbidol (Umifenovir) Pharmstandard marketed Viral fusion inhibitor Viral hemagglutinin (envelope protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Viral fusion inhibitor class)

  1. Pharmstandard · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Arbidol (Umifenovir) — Competitive Intelligence Brief. https://druglandscape.com/ci/arbidol-umifenovir. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: